Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Anti-infectives Giglione & Meinnel Peptide deformylase as an emerging target for antiparasitic agents Peptide deformylase as an emerging target for antiparasitic agents Carmela Giglione & Thierry Meinnel Institut des Sciences Végétales, UPR2355, Centre National de la Recherche Scientifique, Bâtiment 23, 1 avenue de la Terrasse, F-91198 Gif-sur-Yvette cedex, France. http://www.ashley-pub.com Review 1. Introduction 2. The PDF family: a new, growing sub-family of the HEXXH-containing metalloprotease super-family 3. The function of PDF orthologues in eukaryotes 4. Many parasitic illnesses and various PDFs to inhibit 5. Parasite PDFs as drug targets 6. Expert opinion: new anti-parasitic drugs are needed and PDF is a target of choice Acknowledgements Bibliography Websites Peptide deformylases (PDFs) constitute a growing family of hydrolytic enzymes previously believed to be unique to Eubacteria. Recent data from our laboratory have demonstrated that PDF orthologues are present in many eukaryotes, including several parasites. In this report we aim to explain why PDF could be considered to be a potent target for human and veterinary antiparasitic treatments. Keywords: antibiotic, antiparasitic, Chagas’ disease, deformylase, malaria, plasmodium, sequence homology, sleeping sickness, target, trypanosomatids Emerging Therapeutic Targets (2001) 5(1):41-57 1. Introduction - Detecting and stabilising deformylase activity in vitro Polypeptide deformylase (PDF) was first detected in crude bacterial extracts more than 3 decades ago [1,2]. This finding was the logical extension of previous studies, which had shown that, although protein synthesis started at a N-formylmethionine in bacteria, the N-formyl group and often the methionine itself were absent from the N-termini of mature proteins [3,4]. The deformylation step is part of the methionine cycle [5]. Deformylation plays a crucial role in this process as it is necessary for subsequent removal of the unblocked methionine by methionine aminopeptidase (MAP). MAP action is an essential part of the N-terminal maturation process in all cells (for further details and references see also [6,7]). The presence of an N-formyl group on the methionine residue at the start of nascent polypeptides in bacteria seemed to contrast with the situation in eukaryotes and Archae, in which nascent proteins synthesised in the cytoplasm start with a free methionine. However, it was known that proteins synthesised in eukaryote organelles also start with an N-formyl methionine [8]. Most of the sequences of mitochondrial proteins obtained from fungi and mammals indicate that the N-formyl group is retained. It was therefore concluded that PDFs were unique to Eubacteria [9]. Data obtained at the end of 1960s indicated that PDF activity was very unstable and was lost upon any attempt at molecular fractionation. This lability prevented further characterisation of the protein for 25 years. The PDF gene (def or fms) from Escherichia coli was finally cloned in 1993 [9,10]. PDF was then overproduced and the resulting protein characterised in 1995 [11]. It was found that a metal cation was required for activity and the nature of the three metal ligands was determined [12]. It is now 41 2001 © Ashley Publications Ltd. ISSN 1460-0412 42 Peptide deformylase as an emerging target for antiparasitic agents generally accepted that bacterial PDF are linked to a very unstable metal cation (Fe2+) and that the atmospheric oxidation of this cation rapidly and irreversibly inactivates the enzyme [13-15]. This accounts perfectly for the instability of PDF activity. The ferrous enzyme remains stable for less than one minute in vitro. The conditions required for the stabilisation of deformylase activity were not determined until 1998. They involve the use of either: • reactive oxygen species scavengers such as TCEP (Tris(2-carboxy- ethyl)-phosphine) and catalase, or • the early replacement of the iron cation by metal cations insensitive to oxygen such as nickel [13,16] or cobalt [17,18], both of which preserve enzyme activity, although cobalt much less so than nickel. Several in vitro assays of PDF activity have recently been developed and have proved very useful for optimising conditions [19-21]. It should be noted that determining the conditions required for stabilisation of the metal cation and therefore of the activity of a new PDF species remains a crucial and difficult step. Since many new PDFs (see section 2) have recently been discovered, before any in vitro data are obtained, it cannot be excluded a priori that metals other than iron and nickel may give them full deformylase activity. 2. The PDF family: a new, growing sub-family of the HEXXH-containing metalloprotease super-family This section of the review (and part of the next) will take advantage of many in silico data [101-109]. Such data are not yet regarded as ‘fact’ in the same way that in vitro/vivo data are, but this may change as our data sets enlarge and more supporting evidence accumulates. For instance, these in silico data [6] led most recently to Pei’s work with the Plasmodium PDF (see review by Pei, same issue) and our own most recent work [7]. 2.1 Three conserved motifs and a conserved arginine build the active site of eubacterial PDFs PDF was initially believed to occur in eubacteria only. To date, more than 90 eubacterial PDF sequences © Ashley Publications Ltd. All rights reserved. have been determined [110]. Protein sequence alignments have identified only 3 sets of well-conserved residues, motif 1 {gφgφaapQ}, motif 2 {EgCφs} and motif 3 {HEφDHlxg} (where φ is any hydrophobic aliphatic amino acid, with L > I > M > V; see Figure 1 and [6,22]). Based on the 3D-structure (see references quoted in [6]) and taking into account site-directed mutagenesis data, it is now clear that the three motifs build: • the three sides of the active site, and • part of the hydrophobic pocket in which the methionine side chain of the substrate is buried. More precisely, the two residues of motifs 1 and 3 shown in bold (see above) directly contribute to catalysis, whereas the three underlined residues are involved in binding to the metal cation. The acidic side chains of the two residues shown in italics hydrogen bond with the guanidium of a conserved, buried arginine located between motifs 2 and 3. This arginine is generally located in the vicinity of a conserved valine (see VXR in Figure 1). Conservation of the residues of the motif shown in lower case appears, a priori, not to be strictly required although the chemical nature of these residues (small, hydrophobic and/or hydrophilic) is known to play a role in generating the correct 3D structure of the active site. Thus, a PDF may have activity, even in the absence of several of the conserved residues of the 3 motifs, especially those of motif 1 [23]. Analysis of the hydrophilic/hydrophobic nature of the side chains of the residues of the various secondary structure elements identified in the 3D-structure of the E. coli enzyme strongly suggests that all PDFs have a near-identical 3D folding pattern [22]. Demonstration of the importance of the HEXXH sequence of motif 3 and its actual role in catalysis led to the early assignment of PDF to the HEXXHcontaining metalloprotease super-family [24,25]. Indeed, the active site of bacterial PDF has a secondary superstructure common to thermolysins and matricins, the other two sub-families of the super-family [26]. Extensive structural similarity between PDF and matricins was also observed [23]. However, the nature and location of the third metal ligand, the cysteine of motif 2, differs from those of thermolysins and matricins. For this reason, PDFs were classified as a third, novel, sub-family. Emerging Therapeutic Targets (2001) 5(1) Giglione & Meinnel 43 These structural data are important in definition of the criteria for membership of the PDF family and for deformylase activity. 2.2 A 2.2.1 phylogenetic tree for PDFs Two classes of PDF in Eubacteria From the sequence data obtained in bacteria and from an analysis of the sets of deletions and insertions (called I1 and I2 in Figure 1) located between identified secondary structures elements, it was concluded that PDFs can be divided into at least two major families [6]. Class I is typified by the E. coli enzyme and the PDF of all Gram-negative bacteria fall systematically into this class (Figure 2). Class II PDF is typified by Bacillus stearothermophilus PDF and contains PDF from Mycoplasma and Gram-positive bacteria with low G+C content (Figure 2). However, if two PDF occur in such Gram-positive bacteria, the second is often a Class I enzyme. PDF homologues significantly dissimilar to both these classes were found, also in Gram-positive bacteria with low G+C content, such as Clostridium beijerinckii. Finally, the complete genome sequence of the actinomycete Streptomyces coelicolor revealed the presence of four def genes. This corresponds to the largest number of PDF genes detected in any eubacterium to date. Interestingly, one of the four PDF of this actinomycete (S. coelicolor 1/4 in Figure 2) diverges from all other known PDFs. It has been reported that actinomycetes naturally produce a molecule with anti-PDF activity, actinonin [27,28]. However, actinomycetes are themselves resistant to actinonin, possibly due to the acquisition of an actinonin-resistant PDF. This could explain the presence of this divergent PDF in actinomycetes. Alternatively, a function other than the classic deformylation of nascent polypeptides may account for this unusual PDF and the redundancy of def genes in S. coelicolor. 2.2.2 The PDFs from higher Eukaryotes Analysis of the recently produced sequences of the complete genomes of several higher eukaryotes surprisingly revealed the presence of PDF orthologues [6]. For instance, two Class I PDFs were identified in the nuclear genome of both monocotyledonous and dicotyledonous flowering plants [7]. A PDF sequence has also been identified in the genome of the liverwort Marchantia polymorpha. This indicates that PDFs are found in all higher plants (Embryophyta). These enzymes differ from © Ashley Publications Ltd. All rights reserved. eubacterial PDFs in possessing N-terminal pre-sequences that target the corresponding catalytic domains to various compartments of the cell. Hence, plant mitochondrial PDFs (mPDFs) are targeted to the mitochondria only, whereas chloroplast cpPDFs are the only PDFs found in the plastids (see Figure 2 and [7]). The cpPDF are closely related to the PDFs of cyanobacteria (Figure 2), which are believed to be the ancestors of this photosynthetic organelle. mPDF orthologues were also be identified in insects and the tissues of various vertebrates and the corresponding full-length cDNA has been cloned in humans [7]. All animal PDF orthologues have sequences very similar to those of mPDFs and are clearly derived from the same branch of the PDF phylogenetic tree (Figure 2). The bacterial sequence most similar to those of the various mPDFs is the divergent PDF from S. coelicolor (Figure 2). 2.2.3 The PDF of lower Eukaryotes PDF sequences have also been found in the genomes of various eukaryotic protists. A cpPDF (i.e., a PDF resembling the plastid PDFs of plants) was identified in the malaria agent Plasmodium falciparum and is thought to be targeted to the apicoplast [7,29]. A PDF was also identified in the amoeba Dictyostelium discoideum [7]. This PDF, which is probably targeted to the mitochondria, more closely resembles a Class II PDF (Figure 2). Finally, two different PDF orthologues were found in the Kinetoplastids, Trypanosoma spp. and Leishmania major (Figure 2; [29]). These PDF species are clearly different from Class I and Class II PDFs and we now propose that they should be classified as a new class, Class III. 2.2.4 The PDF orthologues of Archae PSI-BLAST [30] is now recognised to be a powerful tool for identifying biologically relevant sequence similarities. Using this program with several PDF sequences, we recently identified for the first time two new sequences from Archaea displaying strong similarity to PDF (Figure 1 and Figure 2). These archaeal PDFs were found in the euryarchaeota Methanothermobacter thermoautotrophicus (Genbank accession number AE000809) and Methanothermus fervidus (Genbank accession number CAA70987). These two sequences are most closely related to the sequences found in kinetoplastids (i.e., Class III PDFs). A specific feature of archaeal PDFs is the occurrence of a distal insertion between motifs 2 and 3 (Figure 1). Given the alternation of Emerging Therapeutic Targets (2001) 5(1) I2 Motif 1 © Ashley Publications Ltd. All rights reserved. TREQRLKERVAARMELEAQVKSR-VACYPHRSLTRPA-LRLERHQVNTP-LFHSQLLNLNKMATDLQ—----———-CISFSAPKGHWDAAI T. cruzi1/2 T. brucei FTLFD—————-------NSVFINPVNLDEEVWRAEAARQGMSWVAFEEEKMREL-RAEGLTGFAWEPCASSGF-LLHYIERPLTVRMRALDE EGCφS VXR -VTRFDEDEMIGRTLEIVYLFLNPRIISEEG——---------------——————————— TVYRFEKCGSRNE-—RELVSRPYRVVVDGDYI Methanothermobacter NP -VLIKGHPNEA—--—-NFEVWVNPTVPGYDDRHSIAP——-----------—————————-MYGMWENCISCGA-CTAWVIRPQSITCSGLDE T. brucei T. cruzi1/2 -ILIKSNPDET-----EYEVWVNPSVPGYDDRNAVAP----—————---------————-MYGMWENCISCGT-ATAWVVRPQRITCSGYDE -VLIKSHPDEE—----VFEVWVSPSVPDYDARTSIAP--—-----------————————-MYGMWENCISCGA-TAAWVIRPQSVTCSGWDE L. major2/2 L. major1/2 FTLFD—————-------GSVFINPVNLDLLEVEAAGSRSGM-PIAEAEAQWVASCRREGKTCFAWEPCASCCF-LMHYIERPATVRIRAIGA T. cruzi2/2 —IAVHVTDENGT—-LYSYALFNPKIVSHSVQQC-------------—————————————YLTTGEGCLSVDRDVPGYVLRYARITVTGTTL FLLKLPSQEGLNCPNFPLTAFFNPKIKLIDQDNN-------------—————————————TITMLESCLSVPN-IFAHVQRSKRCIITFLDI B. stearothermophilus --IVWNALYEKRKEE-NERIFINPSIVEQSLV--------------——————————————KLKLIEGCLSFPG-IEGKVERPSIVSISYYDI D. discoideum Motif2 P. falciparum Central insertion --IVIDVSENRDE—--—RLVLINPELLEKSG--------------——————————————-ETGIEEGCLSIPE-QRALVPRAEKVKIRALDR gφgφaapQ E. coli Lr MDDADLKKLLRFTITEKRVIEKLQIPPDAFLPLL-FSIRFGGDW—----———-SLRKNSSRFMAIKEK AREKRLKDRVAARLELEAQVKSR-VACYPHRSLTRPA-LRLDRTQVNTP-LFQSQLLSLKKMASDLR—----———-CISFSAPKGHWDATV L. major1/2 Methanothermobacter SSNSSGSFADSSRPYVPGQAVQE—-TYPIIQLPARSLWCRQYALDARRVAQGEYAGLISQVREARHYYQ—---——YPSMSAPQTGWNVQM SSSPSFKETVEGKLEKEAEALRR-VACYPHRSMTRPV-MPVPTSQILSP-VFMSSLMDLNQLATGLH—----———-CLSFSAPKAHWDAAV L. major2/2 ????LCAPQIGWNVQM T. cruzi2/2 MITMKDIIKEGHPTLRKVAEPVPLPP-SEEDKRILQSLLDYVKMSQDPELAAKYGLRPGIGLAAPQINVSKRM FILFYFFYNILIKFKMEIVNISKNGVKVGNRVLREKALPWS-——KEKLNDVRRVEKLLEKMYKEMKDCT----———GTGIAAPQIGVNKQL D. discoideum B. stearothermophilus SNIKQKRKGSLYLLKNEKDEIK—IVKYPDPILRRRSEEVT-——NFDDNLKRVVRKMFDIMYESK------—————GIGLSAPQVNISKRI P. falciparum SVLQVLHIPDERLRKVAKPVE-——EVNAEIQRIVDDMFETMYAEE------—————GIGLAATQVDIHQRI I1 MLRHLFRCT——AAWAPKRSA T. brucei N-terminal pre-sequence MLSRLSRTVPLLG——PRRSA T. cruzi1/2 E. coli MRRCVPWRRLVCGGTSLLRGGVDAGGAPL L. major1/2 ??????????????????????????? MRTSAAAAVAAAAHAGVRALHTATGVAGNSCGASPRATVALPPHSGLTLPSFTRCGASSAAFITRAHSVG—CCGCAAAVKQHRLYSSHGC L. major2/2 MLMYYSLSLFNLIICCNVTSIYGYIHNVRSLEPYIKNDQIKNYS D. discoideum N-terminal pre-sequence P. falciparum Figure.1: Alignment of eukaryotic protist PDFs 44 Peptide deformylase as an emerging target for antiparasitic agents Emerging Therapeutic Targets (2001) 5(1) HGN———-------————HKVQVLDGMRARCLMHELDHLMGKTIFHQAVGPEFVVSSVAMAQRYLWPANFPSAEAYVTTPGQFFDYVQNETV L. major1/2 © Ashley Publications Ltd. All rights reserved. HEφDHLXG IPPGMEWWYAQNVREEFSNEQIGQ ??PGMEWWYAQNMQQHFQDARLNQ IPPGMEWFYAQSMNQQFEDARLSH L. major1/2 T. cruzi1/2 T. brucei PDF amino acid sequences from eukaryotic protists were aligned using ClustalX software and by hand. The sequence indicated as Methanothermobacter corresponds to the protein from Methanothermobacter thermoautotrophicus, Genbank accession number AE000809. The three previously defined motifs and the other conserved residues are shown in bold-typeface. A series of question marks indicates unknown parts of the sequence. Special features are indicated above the sequence. LDRKFEDGIYPGCEQDRQQRIELTAMEEIQRNVWRKEKAKRKEGGQQCGRGDVTAVEDDDGSGAAGAR C-terminal extension L. major2/2 A LRAVLDPLDLKIRLKRLEKPLRFTGSGAYGVAHEMEHLEGEESEGTPFWEFEYEIEE HGK——————-------—PFTVTLDKMRARMALHELDHLQGVLFTRRVVDTDHVVPMEGFVTMSDWSDDYRGCPARTPTRSFVSDAVPDGNL L. major2/2 Methanothermobacter DGH—————-------——PFEVTLEKMRARMALHELDHLSGVLFTRRIPDSNHVVPLEGFSTLSGWSDDFPSLEAPQTFLYTTLTSPYTF T. cruzi2/2 YGN——————-------—EKTELLDGMRARCLMHELDHLTGKTILHQALGPEFIGSGIAMGQ?????????????????????????????? DGE————-------———EVTLRLKGLPAIVFQHEIDHLNGIMFYDRINPADPFQVPDGAIPIGR B. stearothermophilus YGN—————-------——EKTEVLDGMRARCLMHELDHLSGKTILDQAQGPEFIVSGIAMGQRDLWPPNFPSAEAYMTSPHQFFDYVKNGPI TGK—————-------——ERIIEADGILAACFQHEYDHLLGKIFIDRIDKSELSNKLIYTTELTEDNLREIFKLHGDFQIIK T. brucei NGY————-------———KHLKILKGIHSRIFQHEFDHLNGTLFIDKMTQVDKKKVRPKLNELIRDYKATHSEEPAL D. discoideum T. cruzi1/2 DGK——————-------—PFELEADGLLAICIQHEMDHLVGKLFMDYLSPLKQQRIRQKVEKLDRLKARA dispensible C-terminus domain P. falciparum Motif3 E. coli Distal insertion Figure.1: Alignment of eukaryotic protist PDFs (continued) Giglione & Meinnel 45 Emerging Therapeutic Targets (2001) 5(1) 46 Peptide deformylase as an emerging target for antiparasitic agents hydrophobic and hydrophilic residues in this insertion, its only effect is likely to be the slight extension of an antiparallel β-sheet far from the active site. However, it should be stressed that motif 1 is only weakly conserved in this species. Thus, it is clear that, in contrast to what was believed until very recently, PDF orthologues are not restricted to Eubacteria, but instead occur in most of the branches of the phylogenetic tree of living organisms (i.e., also in the Archaea, lower and higher eukaryotes). However, some organisms, such as nematodes, fungi and most Archaea, clearly lack PDF orthologues. Of course, it may be possible that these organisms have a PDF with homology below the BLAST threshold, but in our opinion this is unlikely. Indeed, searches in various databases were achieved unsuccessfully by various and different means. Since new complete genome sequences will become available in the next few years, it is therefore of value to identify those organisms that do not contain a PDF. 3. The function of PDF orthologues in Eukaryotes. The detection of so many PDF orthologues in organisms other than eubacteria was unexpected. However, the detection of these orthologues does not necessarily imply that their role is the same and that their activity in eukaryotic cells is the cleavage of N-formyl groups from nascent polypeptides. 3.1 Do all PDF orthologues display deformylase activity? 3.1.1 Plant PDF orthologues Two plant PDFs have recently been shown to complement a def Ts bacterial strain and deformylation activity was measured in vitro [7]. Analysis of the N-terminal sequences of many chloroplast-encoded proteins indeed reveals systematic deformylation and the subsequent removal of the first methionine in some cases, depending on the nature of the second residue (see data quoted in [7]). Although less complete, a similar analysis in plant mitochondria led to the same conclusion [31-35]. These two sets of data indicate that deformylation of nascent polypeptides is performed efficiently in plant organelles. © Ashley Publications Ltd. All rights reserved. 3.1.2 Animal PDF orthologues Our group has recently obtained convincing evidence that mRNAs encoding proteins homologous to mitochondrial PDF are expressed by the nuclear genomes of insects, fish and humans [6,7,29]. Animal PDFs are derived from the same common ancestor and from the same original function as the homologues identified in the mitochondria of higher plants (mPDF; Figure 2). Thus, they are presumably involved in the removal of the N-formylmethionine from newly synthesised proteins in animal mitochondria, which would make it more difficult to use inhibitors of these enzymes in human therapeutics. H o w ever, an al ys i s o f th e s eq u en ces of mitochondrially-encoded proteins in animals has shown that virtually all retain their N-formyl group, as if PDF was not present or active in this organelle (see data in [6,7]). N-terminal sequence data are available for 6 such proteins in cattle. None of these proteins were found to undergo N-deformylation [36-41]. Additional unpublished data strongly suggest that all mitochondrial proteins retain their N-formyl group in bovine systems (see discussion in [7]). The human PDF sequence was studied with Target P software [42,104], for prediction of the subcellular location of proteins. It was predicted that this protein would be targeted to the secretory pathway, whereas all plant mPDFs were predicted to be located in the mitochondria. In contrast, the mouse PDF amino acid sequence, derived from its full-length cDNA (T. Meinnel, unpublished results), was studied with the same software and was predicted with a high probability to be routed to the mitochondria. Clearly, animal PDFs require experimental studies before any definitive conclusions can be drawn about their actual subcellular location. Even if animal PDFs were present in the mitochondria, their structure might account for their intrinsic absence of deformylase activity. We have observed that the conserved hydrophobic residue of motif 2 (generally a leucine; see 2.1 and Figure 1) is systematically replaced by a hydrophilic residue (i.e., a glutamate) in vertebrate PDFs. Given the importance of this residue in bacterial PDF [22,25], this change is likely to have profound consequences for the hydrophilic activity of PDF. Indeed, the side chain of this leucine makes hydrophobic contact with that of one of the conserved hydrophobic residues of motif 1. This contact has two major effects: (i) the closing of one end of the active site and (ii) on the location of the Emerging Therapeutic Targets (2001) 5(1) Giglione & Meinnel 47 Figure 2: A phylogenetic tree for PDF reveals three distinct classes. Class 1 PDF cpPDF Arabidopsis thaliana Plasmodium falciparum cyanobacterial PDF Tomato Calothrix Rice Alfalfa Barley Synechocystis Aquifex aeolicus Prochlorococcus marinus Heliobacter pylori Rickettsia prowazekii Borrelia burgdorferi Vibrio cholerae1/2 Treponema pallidum Escherichia coli Deinococcus radiodurans Haemophilus influenzae Thermus thermophilus Neisseria gonorrhoeae Myobacterium tuberculosis Pseudomonas aeruginosa1/2 Pseudomonas aeruginosa2/2 Clostridium acetobutylicum Thermotoga maritima Chlamydia trachomatis Bacillus subtilis1/2 Legionella pneumophila Dictyostelium discoideum Mouse Mycoplasma pneunomiae Rat Animal PDF Human Staphylococcus aureus Bacillus stearothermophilus Fish Fruit-fly2/2 Bacillus subtilis2/2 Fruit-fly1/2 Streptococcus pyogenes1/2 Enterococcus faecalis Mosquito Streptomyces coelicolor1/4 mPDF Class 2 PDF Corn Wheat Tomato Arabidopsis thaliana Alfalfa Streptococcus pneumoniae2/2 Clostridium beijerinckii Mycoplasma thermoautotrophicum Trypanosoma cruzi2/2 Methanothermus fervidus Leishmania major1/2 Trypanosoma brucei Trypanosoma cruzi1/2 Leishmania major2/2 archaeal PDF Class 3 PDF From the > 120 sequences of PDF orthologues available in databases, 56 PDF sequences were selected as representative of the sequence diversity of this protein. The sequences were aligned with ClustalX software and a phylogenetic tree constructed with TreeView1.6. A number (1, 2 or 4) indicates that the sequence is one of the two (or four) PDF species of this organism. cpPDF = plastid PDF, mPDF = mitochondrial PDF. backbone NH which makes a contact with the oxygen of the formyl moiety of the substrate. We have constructed a model of the active site of human PDF (Figure 3). Although it is only a working model, it suggests that the result of replacing the leucine by a glutamate alone is considerable movement (5 Å) of this side chain. This leads to the active site becoming larger and open to the outside, unlike that of E. coli PDF. Thus, vertebrates PDFs may well have acquired a new substrate specificity that is currently unknown. Further study of this issue is required before the use of anti-PDF drugs is extended. As no in vitro analysis has yet been reported, the presence of PDF orthologues in vertebrates remains a mystery. One possible reason for the presence of PDF © Ashley Publications Ltd. All rights reserved. homologues in animals may be that these proteins are remnants of ancient PDFs that no longer function in deformylation in the mitochondria. It is not known whether these homologues have substrates outside of the mitochondria or whether the product of the PDF open reading frame has acquired another function or location in animal cells. 3.1.3 cpPDF from Apicomplexa and green algae No protein sequences from the apicoplast of Plasmodium falciparum are currently available, but the strong resemblance of this organelle to the chloroplast of the green alga Chlamydomonas reinhardtii makes it possible to make certain predictions. In this green alga, protein sequences for plastid-encoded proteins Emerging Therapeutic Targets (2001) 5(1) 48 Peptide deformylase as an emerging target for antiparasitic agents Figure 3: A 3D model of human PDF suggests an opening of its active site Glu Motif 2 5Å 3Å Leu Motif 3 Motif 1 The amino acid sequence of the human PDF sequence was superimposed over that of E. coli PDF and its 3D structure reconstructed by homology modelling with the known crystal structure [96], using SwissPdbViewer [104]. Minimisation was carried out with the Insight II package (MSI). The catalytic metal cation is shown as a light blue sphere. are available and provide clear evidence of deformylase activity (see data quoted in [29]). This would be consistent with the existence of PDF activity in the apicoplast of Apicomplexa. However, only three proteins of the apicoplast of P. falciparum, namely ribosomal proteins S3 and L14 and ORF105, would be predicted to undergo removal of the first methionine. The removal of the first methionine would be catalysed by the apicoplast MAP recently identified on chromosome 5 of P. falciparum, which resembles its plant counterpart [7]. More generally, it should be borne in mind that Apicomplexa display significant molecular similarity to plants, indicative of a common evolutionary origin [43,44]. 3.1.4 Class III PDFs Class III PDFs remain difficult to analyse. First, no sequence data are available for proteins synthesised in the mitochondria of kinetoplastids. Second, we have cloned and overexpressed the PDF from Trypanosoma brucei in E. coli (C. Lazennec and T. Meinnel, unpublished results). The full-length protein sequence and three N-terminally truncated variants, unlike plant PDFs, were unable to complement a defTs bacterial strain. Nevertheless, using the same strategy © Ashley Publications Ltd. All rights reserved. with plant PDFs, we found that it was not easy to achieve complementation with the full-length mitochondrial form [7]. We therefore cannot exclude that we did not express the appropriate, most soluble form of T. brucei PDF in the bacterium. Third, we found that the purified protein from T. brucei had no significant deformylase activity in vitro, with a kcat/KM greater than 1 M-1 s-1 (C. Lazennec and T. Meinnel, unpublished results). Given the difficulties in stabilising the metal cation in the enzyme, no definitive conclusion can be drawn from experiments with negative results such as this, as previously indicated (see section 1). Finally, we have found that the PDF orthologue of T. brucei has a lysine instead of the crucial glutamine in motif 1 (Figure 1). A post-translational modification that does not occur in E. coli has already been reported for urease involving carbamylation of the side chain of the lysine of the active site [45]. We therefore wondered whether such a modification could occur also in kinetoplastids. Unfortunately, replacement by site-directed mutagenesis of the lysine by a glutamine, which mimics a carbamyl-lysine did not improve PDF activity in vitro or in vivo. Emerging Therapeutic Targets (2001) 5(1) Giglione & Meinnel 49 No information is yet available concerning the second type of PDF from kinetoplastids. The sequence of this PDF is more closely related to other PDFs than to that from T. brucei. In particular, it contains the important glutamine of motif 1. It is not yet clear whether this PDF has deformylase activity, although we believe that this may well be the case. Last but not least, the presence of PDF orthologues in Archaea remains a true mystery. In this organism, it has been known for twenty years that there is no N-formylation of nascent polypeptides [8]. We believe that, as in the case of human PDF (see 3.1.1), this protein may have a slightly different proteolytic activity. PDF activity is essential in the organelles of some eukaryotes but has probably disappeared from others, including humans 3.2 Given current knowledge and the data available on plant mPDFs, animal PDFs appear to be inactive in mitochondria. This raises the questions as to why the protein deformylation is not required in animal cells but does occur in other organisms, such as plants and many eukaryotic protists. Correlation between gene number and deformylase activity in organelles 3.2.1 To date, although many PDF genes have been sequenced, none has been identified in an organelle genome. The same is true for other crucial enzymes such as MAP and aminoacyl-tRNA synthetases (aaRS) (for a review on aaRS see [46]). The mitochondrial genome of the protozoon Reclinomonas americana contains the largest (97) collection of genes identified to date in an organelle [47]. It has been suggested that this genomes resembles the ancestral genome of mitochondria, but it contains no aaRS, PDF or MAP gene. Interestingly, the number of genes in R. americana is similar to that of the smallest bacterial genome described so far, Mycoplasma genitalium. It contains 470 ORFs, of which only 250-350 are considered to be strictly required for cell survival [48]. Like aaRS and MAP, its PDF genes are absolutely required for survival. Thus, like aaRS and MAP, PDF genes were among the first genes corresponding to essential functions to be transferred from the organelle to the nucleus. This raises questions concerning (i) the actual role of N-terminal protein processing and (ii) the reasons why it has been retained in the organelles of some © Ashley Publications Ltd. All rights reserved. organisms (i.e., all plastids and the mitochondria of higher plants and of some protists) but has disappeared from the mitochondria of animals and fungi (humans, C. elegans and S. cerevisiae for instance). It should be borne in mind that the genomes of plants and the genomes of protist’s organelles encode 30-100 proteins versus only nine in yeast and 13 in animal mitochondria. Moreover, in the mitochondria of all animal including C. elegans, which contains no PDF, a common set of 13 proteins is synthesised: 7 subunits of NADH:ubiquinone oxidoreductase, the three subunits of cytochrome oxidase, cytochrome b and subunits 8 and 9 of ATP synthase. It seems most likely that the genes encoding several proteins strictly requiring deformylation to achieve their final function were retained in the organelles genomes of some organisms, but not in those of others such as yeast. The loss of proteins requiring deformylation would thus have led to the loss of the deformylase function. Clearly, none of the 13 proteins encoded by animal mitochondria require deformylation for full activity. Determination of the smallest set of physiological substrates requiring the deformylation function 3.2.2 The set of additional proteins encoded by plant organelles includes ribosomal proteins, subunits of RNA polymerase, translation factors and the proteins involved in the specific functions of the organelle, such as the large subunit of Rubisco in plastids [49-52]. Rubisco is one of the most abundant proteins on earth and is the motor of photosynthetic function. This protein is known to undergo further processing in the plastids. Once PDF and MAP have removed the N-formylmethionine of the large subunit of Rubisco, the serine in position 2 is removed and this is followed by N-acetylation [53] or even further N-methylation [54]. Given the crucial role of Rubisco, we cannot exclude the possibility that PDF and MAP have been retained to ensure the correct processing at least of this protein. However, the impact of these modifications on Rubisco activity and stability is unknown and the 3D structure of this molecule provides no further insight into this issue [55]. No Rubisco is present in the apicoplast of P. falciparum, in which deformylation is clearly required [56]. The reason for the necessity of N-formyl removal probably lies in the function of one or several of the ribosomal proteins (i.e., translation machinery) encoded by all organelle genomes (mitochondrial and plastid). Emerging Therapeutic Targets (2001) 5(1) 50 Peptide deformylase as an emerging target for antiparasitic agents In conclusion, we believe that the requirement for PDF has disappeared only in organisms in which the number of genes in the organelle genome has been reduced to a very small number. This provides strong evidence that the pathway for the processing of the first methionine plays a crucial, general role (for a further discussion see [5]). Thus, it seems probable that deformylation is essential for the function of the organelle, in those organelles in which it occurs. Blocking PDF function should lead to the death of the corresponding organism. The essentiality of PDF will deserve however to be experimentally addressed in each biological system where it is present. 4. Many parasitic illnesses and various PDFs to inhibit Six major tropical diseases, malaria, filariasis, schistosomiasis, African trypanosomiasis, Chagas’ disease and leishmaniasis, together account for the deaths of more than one million people each year and cause enormous suffering in hundreds of millions more [111-113]. Resistance to the drugs currently used to cure most of these diseases is clearly on the increase and new medicines are required in the short-term. PDF function is required in eubacteria but absent in humans. Given that most of the organisms responsible for these major diseases have PDFs, this raises possibilities for the use of inhibitors of PDF as potent medicines. 4.1 Apicomplexa The phylum Apicomplexa includes a large family of unicellular parasites that cause various diseases. This family of protists includes the causative agent of malaria (Plasmodium spp.), opportunistic pathogens associated with immunodeficiency (e.g., the AIDS-associated pathogen Toxoplasma gondii, Cryptosporidium and Sarcocystis) and pathogens of poultry, livestock and shellfish (e.g., Eimeria, Theileria, Babesia). The members of the Apicomplexa have recently been shown to contain a small plastid called the apicoplast [57,58]. The 35 kb sequence of the apicoplast genomes of two Apicomplexa species (i.e., T. gondii and P. falciparum) have been determined [59,102]. These data reveal a high level of conservation of the 25 proteins encoded by these genomes including 17 ribosomal proteins, elongation factor Tu (EFTu), one subunit of the clp protease and the three subunits of RNA polymerase. The apicoplast gen o m e strongly res embles that of © Ashley Publications Ltd. All rights reserved. non-photosynthetic plants, with no genes encoding the proteins of the photosynthetic machinery. The discovery of a plastid in Apicomplexa has rapidly led to suggestions that this organelle would be a good target for antiparasitic drugs. Indeed, apicoplast function has been shown to be required for parasite survival [60,61]. The apicoplast has been shown to be the pharmacological target of many antibiotics known to be specific for eubacteria and organelles. These drugs (e.g., chloramphenicol, clindamycin, thiostrepton, rifamycin, azithromycin, fluoroquinolones) specifically block apicoplast protein synthesis, transcription or DNA replication [62,63]. The blocking of the activities of the plastids with such drugs results in a characteristic pattern of delayed death that contrasts with the more immediate effect seen with drugs such as chloroquine. However, inhibition of the apicoplast EFTu by various drugs, such as kirromycin or enacyloxin IIa, results in the rapid onset of inhibition [64]. Interestingly, plastid function can be blocked by these drugs and the parasite killed at various stages of its sexual development [65]. Although the apicoplast is clearly the site of many crucial metabolic processes, such as branched and aromatic amino acid biosynthesis, it is unclear why the expression of its genome is important for cell survival. No apicoplast gene product appears to play a specific role in processes other than genome expression. However, the functions of several open reading frames of the apicoplast genome are unknown. The key to understanding the essential function of the apicoplast probably lies in the identification of the functions of these genes. To date, P. falciparum PDF is the only species of this group for which a PDF has been described [29]. Given the high level of conservation of apicoplast sequences, there is probably a PDF sequence in all Apicomplexa. No direct proof has yet been provided that the P. falciparum PDF is located in the apicoplast. Nevertheless, the amino acid sequence of this PDF resembles that of cpPDF and it is rooted on the same branch of the PDF phylogenic tree as plant cpPDF (Figure 2). The recent demonstration that cpPDFs are systematically targeted to the plastids of plants strongly suggests that P. falciparum PDF is targeted to the apicoplast [7]. Moreover, like other nuclearencoded apicoplast proteins, this PDF has a bipartite N-terminal pre-sequence consisting of a signal peptide for entry into the secretory pathway and a transit peptide similar to those found in plant proteins Emerging Therapeutic Targets (2001) 5(1) Giglione & Meinnel 51 targeted to the chloroplast, for subsequent import into the apicoplast [66,67]. 4.2 Trypanosomatids possible that other closely related human parasites like Entamoeba spp. (responsible for several intestinal diseases) also contain a PDF that would be sensitive to anti-PDF drugs. Trypanosomatids cause many serious parasitic diseases. The most famous is African trypanosomiasis or sleeping sickness, which is transmitted by the Tsetse fly (Glossina spp.). This disease has re-emerged as a major health problem in sub-Saharan Africa. Sleeping sickness actually covers two distinct diseases with different clinical signs in humans depending on the epidemic area. This reflects the two very different causative trypanosomes that cause them: Trypanosoma brucei gambiense (north west of the African rift) and T. brucei rhodesiense (south east of the African rift). Chagas’ disease is another major disease caused by a trypanosome, Trypanosoma cruzi, in South America. Leishmaniasis is caused by Leishmania major and transmitted by phlebotomine sand-fly vectors. No PDF sequence has been detected in the genome of the nematode C. elegans. This suggests that the nematodes responsible for filariasis such as Brugia malayi are unlikely to be sensitive to anti-PDF drugs. Similarly, although little is known about the number of genes in the mitochondria of Shistosoma spp. [70,71], the mitochondrial genome of another related member of the Platyhelminthes, the turbellarian Echinococcus multilocularis [102], contains a similar number of genes to that of C. elegans. Therefore, these parasites are also unlikely to be sensitive to anti-PDF drugs. The origin, location and function of the two PDFs in trypanosomatids is unknown. Their N-terminal pre-sequence resemble mitochondrial (e.g., L. major and Trypanosoma sequences 1/2 in Figure 1) or plastid import sequences (e.g., Leishmania 2/2 in Figure 1). These flagellates are very closely related to euglenids which, unlike trypanosomatids, display a plastid. Some of these protists are photosynthetic (Euglena gracilis) whereas others are not (Astasia longa). The N-formylation of proteins has been shown to occur and to be strictly required in the two organelles of these organisms [68]. We therefore cannot exclude the possibility that the second PDF is a remnant of the occurrence of an ancient plastid, which has now disappeared. Alternatively, given the high level of similarity between the two PDFs, the second PDF may result from an early duplication of the original gene. There is increasing evidences that PDF would be a good target for new antibacterial agents and many efficient inhibitors of PDF have been described (see accompanying review in this issue and reference [6]). The most efficient agents appear to be hydroxamate [28,72] and thiol derivatives [73-75]. Structure-based drug design could be the approach of choice to improve further their specificity and affinity [76]. Hence, powerful automated NMR methods, aimed at discovering and producing high-affinity ligands, have been described [77] and are currently being used by Hoffmann-Laroche to screen for inhibitors of PDF [78]. It is now clear that the availability of large amounts of purified parasitic PDF may become a limiting step. Little is yet known about the potency of parasite PDFs as drug targets, but promising results have been obtained for P. falciparum PDF. 5. Parasite PDFs as drug targets 5.1 Plasmodium 4.3 Other parasites The amoeba D. discoideum possesses a PDF that is very likely to be routed to its mitochondria [7]. The mitochondrial genome of this species encodes a large number of proteins (> 40). In this respect, it closely resembles the genome of plant mitochondria, in which PDF is known to be functional. The mitochondrial genome of Acanthamoeba castellanii [69] encodes a similar number of genes and based on the reasoning described above (see 3.1) is likely to possess a PDF. This amoeba is responsible for several opportunistic infections in humans. It is therefore © Ashley Publications Ltd. All rights reserved. PDF is naturally inhibited by actinonin Studies with P. falciparum PDF have not yet been reported in vitro, but the resemblance of this protein to tomato cpPDF led us to study this tomato PDF as a model for PDFs from the Apicomplexa. We showed that this protein was as sensitive as bacterial PDF to the antibiotic actinonin [79]. The antibacterial properties of actinonin were discovered in 1962 [27] but the specific intracellular molecular target of this molecule in bacteria was only recently shown to be PDF [28]. Actinonin has also proved to be a potent inhibitor of Plasmodium growth with a half-maximal inhibitory Emerging Therapeutic Targets (2001) 5(1) 52 Peptide deformylase as an emerging target for antiparasitic agents concentration (3 µM) lower than that of the most sensitive bacteria [56,79]. However, actinonin has no effect against malaria in vivo in a rodent model of malaria. Although actinonin is known to inhibit a variety of other enzymes (e.g., matricins; see our conclusion in [6]), the effect of actinonin on Plasmodium growth strongly suggests that PDF is a good target for new antimalarial agents, particularly for many of the diseases caused by members of the phylum Apicomplexa. As recently discussed however [79], the essentiality of PDF in P. falciparum deserves to be proved. 5.2 How can we improve the in vivo potency of anti-PDF drugs? PDF is a peptidase that recognises three contiguous peptide bonds, including the amide of the formyl group [23,74]. It is therefore not surprising that the most potent inhibitors belong to peptide derivative series (see discussion and references in [6]) and that non-peptide inhibitors of PDF, such as those described by Pfizer and Merck, lack potency [80,81]. The rational design of peptide derivatives has led to the discovery of several potent drugs (see the review by Pei, same issue). However, peptides have limitations in terms of bioavailability and activity when given by the oral route. Actinonin has low potency in vivo in humans both as an antibacterial drug [82] and as an antimalarial agent [56]. It has been suggested that this is due to metabolic inactivation. Peptide mimicry (for a recent review read [83]) is therefore one way in which the bioavailability of actinonin and of other thiol derivatives could be improved. Fortunately, the active site of PDF has been reported to be very similar to that of matricins (see 2.1), a class of proteases of broad therapeutic interest. As a result, most of the strategies to improve the in vivo stability of anti-PDF drugs take advantage of the lessons learned with anti-matricin drugs. It was found early on that the presence of a sterically demanding group at the P2’ position (such as C(CH3)3) increases the activity of drugs given orally by preventing hydrolysis at adjacent hydrolysable centres. This led to the synthesis of the earlier ‘peptoid’ matricin inhibitor BB-2516 by British Biotech, this drug also being known as marimastat [84]. The synthesis of one inhibitor of this type, BB-3497, with an n-butyl instead of the branched butyl at P1’ in BB-2516 to confer specificity for PDF, was recently undertaken [85]. Another company (Versicor) used a similar approach and an hydroxamic © Ashley Publications Ltd. All rights reserved. inhibitor VRC3324 was synthesised [86]. In both cases, the inhibitors effectively cured septicaemia in mice when administered via the various possible injection routes. Another way to bypass metabolic hydrolysis of the compound is to synthesise β-sulfonyl- and β-sulfinylhydroxamic acids, as described for CGS27023A, a broad-spectrum matricin inhibitor [87]. In the case of PDF, such an approach was successfully developed by Hoffmann-Laroche after they re-discovered actinonin by screening for inhibitors of E. coli PDF [72]. Although drug resistance is frequently observed with such compounds in bacteria, this need not necessarily to be the case in parasites, against which these drugs may be effective. 6. Expert opinion: new anti-parasitic drugs are needed and PDF is a target of choice Parasitic diseases such as malaria are clearly increasing in importance world-wide due to the acquisition of resistance. Hence, P. falciparum malaria caused more than 1 million deaths worldwide among 273 million cases in 1998 [112-113]. Unfortunately, malaria and most of the parasitic diseases caused by PDF-containing protists are not economically attractive targets for the pharmaceutical industry [88]. However, a recent analysis by Jeffrey Sachs, a Harvard health economist, of the economic and social costs of malaria concluded that controlling this disease is highly cost-effective [89]. This led the World Health Organisation (WHO) to instigate the WHO Roll Back Malaria campaign, which seeks to halve the incidence of malaria by 2010. There are also frequent predictions and warnings that global climate changes, induced by greenhouse gases, will result in the world being warmer in the future. If this process of global warming occurs rapidly during the 21st century [90], then the vectors of major parasitic diseases, Anopheles mosquito, Tsetse fly or sand fly, may reach the central or northern regions of Europe and large parts of America. Although some climate change predictions foresee little change in the distribution of malaria for instance [91], the opposite is also predicted in other studies [92-95]. Such difficulties in predicting their own near future should provide northern countries with a major incentive to commit themselves to the search for new drugs to fight parasitic illnesses. Emerging Therapeutic Targets (2001) 5(1) Giglione & Meinnel 53 PDF is clearly one of several promising targets for the treatment of parasitic diseases. Many tools are already available to study the effects of PDF inhibition in vivo and in vitro. Actinonin and other thiopeptide derivatives are already available and have been shown to inhibit Plasmodium growth in a rodent model. PDF is already considered a promising target for new antibacterial agents [6] and many major pharmaceutical companies (e.g., Aventis, British-Biotech, Glaxo, Hoffmann-Laroche, Merck, Novartis, Pfizer, Sm ith Klin e-Beecham) have deve l o p ed high-throughput screening protocols to search for possible anti-PDF drugs. We believe that discovering drugs that, like actinonin, could have both antibacterial and antiparasitic effects should be very easy. This should result in much lower initial investment costs for pharmaceutical companies. A study of the biochemical properties of the various PDFs as well as the differences between them should rapidly help the search for very specific, efficient drugs. This should encourage and stimulate the search by private companies for new drugs aimed at blocking the PDF activity of parasites. This will, as for all new medicines today, require the means and resources of a large pharmaceutical company. 4. MARCKER K, SANGER F: N-formyl-methionyl-S-RNA. J. Mol. Biol. (1964) 8:835-840. 5. MEINNEL T, MECHULAM Y, BLANQUET S: Methionine as translation start signal: a review of the enzymes of the pathway in Escherichia coli. Biochimie (1993) 75:1061-1075. 6. GIGLIONE C, PIERRE M, MEINNEL T: Peptide deformylase as a target for new generation, broad spectrum a n ti m i cr o b i a l a g e n ts . M o l . M i c r o b i o l . (2 0 0 0 ) 36:1197-1205. A recent review of PDF and of its use as a target for antimicrobial drugs. •• 7. •• 8. KOZAK M: Comparison of initiation of protein synthesis in procaryotes, eucaryotes and organelles. Microbiol. Reviews (1983) 47:1-45. 9. MAZEL D, POCHET S, MARLIERE P: Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J. (1994) 13:914-923. Reports the cloning of E. coli PDF using an elegant genetic screen. • 10. • Acknowledgements The authors would like to thank all of their collaborators in Gif/Yvette who have collectively contributed to this work. This work was supported by ATIPE, PCV and MCT grants from the C.N.R.S. to TM and by the Fondation pour la Recherche Médicale. CG holds a post-doctoral fellowship from the Association pour la Recherche sur le Cancer (ARC, Villejuif, France). MEINNEL T, BLANQUET S: Enzymatic properties of Escherichia coli peptide deformylase. J. Bacteriol. (1995) 177:1883-1887. 12. MEINNEL T, LAZENNEC C, BLANQUET S: Mapping of the active site zinc ligands of peptide deformylase. J. Mol. Biol. (1995) 254:175-183. 13. GROCHE D, BECKER A, SCHLICHTING I et al.: Isolation and crystallization of functionally competent Escherichia coli peptide deformylase forms containing either iron or nickel in the active site. Biochem. Biophys. Res. Commun. (1998) 246:342-346. An excellent work on the various means to stabilise PDF activity. Bibliography 14. Papers of special note have been highlighted as: • of interest •• of considerable interest • • ADAMS JM: On the release of the formyl group from nascent protein. J. Mol. Biol. (1968) 33:571-589. A very nice paper on the initial characterisation of deformylase activity in eubacteria. 2. LIVINGSTON DM, LEDER P: Deformylation and protein synthesis. Biochemistry (1969) 8:435-443. 3. ADAMS JM, CAPECCHI M: N-formylmethionine-sRNA as the initiator of protein synthesis. Proc. Natl. Acad. Sci. USA (1966) 55:147-155. © Ashley Publications Ltd. All rights reserved. MEINNEL T, BLANQUET S: Evidence that peptide deformylase and methionyl-tRNA(fMet) formyltransferase are encoded within the same operon in Escherichia coli. J. Bacteriol. (1993) 175:7737-7740. First report of a PDF gene in eubacteria. 11. •• 1. GIGLIONE C, SERERO A, PIERRE M, BOISSON B, MEINNEL T: Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J. (2000) 19:5916-5629. Discovery of functional PDFs in higher eukaryotes. RAJAGOPALAN PTR, YU XC, PEI D: Peptide deformylase: a new type of mononuclear iron protein. J. Am. Chem. Soc. (1997) 119:12418-12419. The first report showing PDF as an iron enzyme. 15. RAJAGOPALAN PT, PEI D: Oxygen-mediated inactivation of peptide deformylase. J. Biol. Chem. (1998) 273:22305-22310. 16. RAGUSA S, BLANQUET S, MEINNEL T: Control of peptide deformylase activity by metal cations. J. Mol. Biol. (1998) 280:515-523. 17. DURAND DJ, GORDON GREEN B, O’CONNELL JF, GRANT SK: Peptide aldehyde inhibitors of bacterial peptide deformylases. Arch. Biochem. Biophys. (1999) 367:297-302. Emerging Therapeutic Targets (2001) 5(1) 54 Peptide deformylase as an emerging target for antiparasitic agents 18. RAJAGOPALAN PT, GRIMME S, PEI D: Characterization of cobalt(II)-substituted peptide deformylase: Function of the metal ion and the catalytic residue Glu-133. Biochemistry (2000) 39:791-799. 19. GUO XC, RAJAGOPALAN PTR, PEI D: A direct spectrophotometric assay for peptide deformylase. Anal. Biochem. (1999) 273:298-304. 20. LAZENNEC C, MEINNEL T: Formate dehydrogenasecoupled spectrophotometric assay of peptide deformylase. Anal. Biochem. (1997) 244:180-182. 21. WEI Y, PEI D: Continuous spectrophotometric assay of peptide deformylase. Anal. Biochem. (1997) 250:29-34. 22. MEINNEL T, LAZENNEC C, VILLOING S, BLANQUET S: Structure-function relationships within the peptide deformylase family. Evidence for a conserved architecture of the active site involving three conserved motifs and a metal ion. J. Mol. Biol. (1997) 267:749-761. The involvement of three conserved motifs in the structure of the active sites of all PDFs. • 23. 24. 25. RAGUSA S, MOUCHET P, LAZENNEC C, DIVE V, MEINNEL T: Substrate recognition and selectivity of peptide deformylase. Similarities and differences with metzincins and thermolysin. J. Mol. Biol. (1999) 289:1445-1457. CHAN MK, GONG W, RAJAGOPALAN PT et al.: Crystal structure of the Escherichia coli peptide deformylase [published erratum appears in Biochemistry 1998 Sep 15;37(37):13042]. Biochemistry (1997) 36:13904-13909. MEINNEL T, BLANQUET S, DARDEL F: A new subclass of the zinc metalloproteases superfamily revealed by the solution structure of peptide deformylase. J. Mol. Biol. (1996) 262:375-386. 26. DARDEL F, RAGUSA S, LAZENNEC C, BLANQUET S, MEINNEL T: Solution structure of nickel-peptide deformylase. J. Mol. Biol. (1998) 280:501-513. 27. GORDON JJ, KELLY BK, MILLER GA: Actinonin: an antibiotic substance produced by an actinomycete. Nature (1962) 195:701-702. 28. CHEN DZ, PATEL DV, HACKBARTH CJ et al.: Actinonin, a naturally occurring antibacterial agent, is a potent d ef o r m y l a se i n h i b i t o r. B i o c h em i s tr y (2000) 39:1256-1262. Reports that actinonin, a natural antibiotic, specifically blocks PDF activity. •• 29. •• 30. 31. MEINNEL T: Peptide deformylase of eukaryotic protists: A target for new antiparasitic agents? Parasitol. Today (2000) 16:165-168. First report of the existence of PDFs in parasites. ALTSCHUL SF, MADDEN TL, SCHÄFFER AA et al.: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. (1997) 25:3389-3402. BRAUN HP, SCHMITZ UK: Purification and sequencing of cytochrome b from potato reveals methionine cleavage of a mitochondrially encoded protein. FEBS Lett. (1993) 316:128-132. © Ashley Publications Ltd. All rights reserved. 32. GABLER L, HERZ U, LIDDELL A et al.: The 42.5 kDa subunit of the NADH: ubiquinone oxidoreductase (complex I) in higher plants is encoded by the mitochondrial nad7 gene. Mol. Gen. Genet. (1994) 244:33-40. 33. HERZ U, SCHRODER W, LIDDELL A et al.: Purification of the NADH:ubiquinone oxidoreductase (complex I) of the respiratory chain from the inner mitochondrial membrane of Solanum tuberosum. J. Biol. Chem. (1994) 269:2263-2269. 34. LETERME S, BOUTRY M: Purification and preliminary characterization of mitochondrial complex I (NADH: ubiquinone reductase) from broad bean (Vicia faba L.). Plant Physiol. (1993) 102:435-443. 35. MAFFEY L, DEGAND H, BOUTRY M: Partial purification of mitochondrial ribosomes from broad bean and identification of proteins encoded by the mitochondrial genome. Mol. Gen. Genet. (1997) 254:365-371. 36. WALKER JE, LUTTER R, DUPUIS A, RUNSWICK MJ: Identification of the subunits of F1F0-ATPase from bovine heart mitochondria. Biochemistry (1991) 30:5369-5378. 37. Y A G I T , H A T E F I Y : I d e n ti f i ca ti o n o f t h e dicyclohexylcarbodiimide-binding subunit of NADHubiquinone oxidoreductase (Complex I). J. Biol. Chem. (1988) 263:16150-16155. 38. FEARNLEY IM, WALKER JE: Two overlapping genes in bovine mitochondrial DNA encode membrane components of ATP synthase. EMBO J. (1986) 5:2003-2008. 39. STEFFENS GJ, BUSE G: Studies on cytochrom c oxidase, I. Hoppe-Seyler’s Z. Physiol. Chem. (1976) 367:1125-1137. 40. STEFFENS GJ, BUSE G: Studies on cytochrom c oxidase, IV. Primary structure and function of subunit II. Hoppe-Seyler’s Z. Physiol. Chem. (1979) 360:613-619. 41. VON JAGOW G, ENGEL WD, SCHÄGER H, MACHLEIDT W, MACHLEIDT I: On the mechanism of proton translocation linked to electron transfer at energy conversion site 2. In Vectorial reactions in electron and ion transport in mitochondria and bacteria. Edited by Palmieri F: Elsevier/North-Holland Biomedical Press; 1981:149-161., 42. EMANUELSSON O, NIELSEN H, BRUNAK S, VON HEIJNE G: Predicting subcellular localization of proteins based on their N-terminal amino acid sequence. J. Mol. Biol. (2000) 300:1005-1016. 43. DZIERSZINSKI F, POPESCU O, TOURSEL C et al.: The protozoan parasite Toxoplasma gondii expresses two functional plant-like glycolytic enzymes. Implications for evolutionary origin of Apicomplexans. J. Biol. Chem. (1999) 274:24888-24895. 44. ROOS DS, CRAWFORD MJ, DONALD RG et al.: Origin, targeting and function of the Apicomplexan plastid. Curr. Opin. Microbiol. (1999) 2:426-432. 45. JABRI E, CARR MB, HAUSINGER RP, KARPLUS PA: The crystal structure of urease from Klebsiella aerogenes. Science (1995) 268:998-1004. Emerging Therapeutic Targets (2001) 5(1) Giglione & Meinnel 55 46. MEINNEL T, MECHULAM Y, BLANQUET S: AminoacyltRNA synthetases: structure, function and occurrence. In tRNA. Edited by Söll D, RajBhandary U: American Society for Microbiology; 1995:251-292., 61. MCCONKEY GA, ROGERS MJ, MCCUTCHAN TF: Inhibition of Plasmodium falciparum protein synthesis. Targeting the plastid-like organelle with thiostrepton. J. Biol. Chem. (1997) 272:2046-2049. 47. LANG BF, BURGER G, O’KELLY CJ et al.: An ancestral mitochondrial DNA resembling a eubacterial genome in miniature. (1997) 387:493-497. 62. MCFADDEN GI, ROOS DS: Apicomplexan plastids as drug targets. Trends Microbiol. (1999) 7:328-333. 63. 48. HUTCHISON CA, PETERSON SN, GILL SR et al.: Global transposon mutagenesis and a minimal Mycoplasma genome. Science (1999) 286:2165-2169. ROOS DS: The apicoplast as a potential therapeutic target in Toxoplasma and other Apicomplexan parasites: some additional thoughts. Parasitol. Today (1999) 15:41. 49. UNSELD M, MARIENFELD JR, BRENNICKE A: The mitochondrial genome of Arabidopsis thaliana contains 57 genes in 366,924 nucleotides. Nature Genet. (1997) 15:57-61. 64. CLOUGH B, RANGACHARI K, STRATH M, PREISER PR, WILSON RJ: Antibiotic inhibitors of organellar protein synthesis in Plasmodium falciparum. Protist (1999) 150:189-195. 50. SHIMADA H, SUGIURA M: Fine structural features of the chloroplast genome: comparison of the sequenced chloroplast genomes. Nucleic Acids Res. (1991) 19:983-995. 65. SULLIVAN M, LI J, KUMAR S, ROGERS MJ, MCCUTCHAN TF: Effects of interruption of apicoplast function on malaria infection, development and transmission. Mol. Biochem. Parasitol. (2000) 109:17-23. 51. SATO S, NAKAMURA Y, KANEKO T, ASAMIZU E, TABATA S: Complete structure of the chloroplast genome of Arabidopsis thaliana. DNA Res. (1999) 6:283-290. 66. WALLER RF, KEELING PJ, DONALD RG et al.: Nuclearencoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl. Acad. Sci. U S A (1998) 95:12352-12357. 52. SCHUSTER W, BRENNICKE A: The plant mitochondrial genome: physical structure, information content, RNA editing and gene migration to the nucleus. (1994) 45:61-78. 67. WALLER RF, REED MB, COWMAN AF, MCFADDEN GI: Protein trafficking to the plastid of Plasmodium falciparum is via the secretory pathway. Embo J. (2000) 19:1794-1802. 68. LUCCHINI G, BIANCHETTI R: Initiation of protein synthesis in isolated mitochondria and chloroplasts. Biochim. Biophys. Acta (1980) 608:54-61. 53. HOUTZ RL, STULTS JT, MULLIGAN RM, TOLBERT NE: Post-translational modifications in the large subunit of ribulose bisphosphate carboxylase/oxygenase. Proc. Natl. Acad. Sci. USA (1989) 86:1855-1859. 54. YING Z, MULLIGAN RM, JANNEY N, HOUTZ RL: Rubisco small and large subunit N-methyltransferases. Bi- and mono- functional methyltransferases that methylate the small and large subunits of rubisco. J. Biol. Chem. (1999) 274:36750-36756. 69. BURGER G, PLANTE I, LONERGAN KM, GRAY MW: The mitochondrial DNA of the amoeboid protozoon, Acanthamoeba castellanii: complete sequence, gene content and genome organization. J. Mol. Biol. (1995) 245:522-537. 55. HARTMAN FC, HARPEL MR: Structure, function, regulation and assembly of D-ribulose-1,5-bisphophate carboxylase/oxygenase. Ann. Rev. Biochem. (1994) 63:197-234. 70. LE TH, BLAIR D, MCMANUS DP: Mitochondrial DNA sequences of human schistosomes: the current status. Int. J. Parasitol. (2000) 30:283-290. 71. 56. WIESNER J, SANDERBRAND S, BECK E, JOMAA H: Seeking new targets for antiparasitic agents. Trends Parasitol. (2001) 17:7. Reports that actinonin blocks Plasmodium growth. LE TH, BLAIR D, MCMANUS DP: Mitochondrial genomes of human helminths and their use as markers in population genetics and phylogeny. Acta Trop. (2000) 77:243-256. 72. APFEL C, BANNER DW, BUR D et al.: Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J. Med. Chem. (2000) 43:2324-2331. Rational design strategy for finding anti-PDF drugs. •• 57. KOHLER S, DELWICHE CF, DENNY PW et al.: A plastid of probable green algal origin in Apicomplexan parasites. Science (1997) 275:1485-1489. 58. M C FA DDEN G I , R E I T H ME , MU N H O L L A N D J , LANG-UNNASCH N: Plastid in human parasites. Nature (1996) 381:482. • 59. 60. WILSON RJ, DENNY PW, PREISER PR et al.: Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum. J. Mol. Biol. (1996) 261:155-172. FICHERA ME, ROOS DS: A plastid organelle as a drug target in Apicomplexan parasites. Nature (1997) 390:407-409. © Ashley Publications Ltd. All rights reserved. 73. •• 74. • HUNTINGTON KM, YI T, WEI Y, PEI D: Synthesis and antibacterial activity of peptide deformylase inhibitors. Biochemistry (2000) 39:4543-4351. Reports that a thiol peptide derivative is a potent PDF inhibitor and has a bacteriacidic effect. MEINNEL T, PATINY L, RAGUSA S, BLANQUET S: Design and synthesis of substrate analogue inhibitors of peptide deformylase. Biochemistry (1999) 38:4287-4295. First report of the potency of thiol peptide derivatives in PDF inhibition. Emerging Therapeutic Targets (2001) 5(1) 56 Peptide deformylase as an emerging target for antiparasitic agents 75. WEI Y, YI T, HUNTINGTON KM, CHAUDHURY C, PEI D: Identification of a potent peptide deformylase inhibitor from a rationally designed combinatorial library. J. Comb. Chem. (2000) 2:650-657. 90. HARTMANN DL, WALLACE JM, LIMPASUVAN V, THOMPSON DW, HOLTON JR: Can ozone depletion and global warming interact to produce rapid climate change? Proc. Natl. Acad. Sci. U S A (2000) 97:1412-1417. 76. GANE PJ, DEAN PM: Recent advances in structure-based rational drug design. Curr. Opin. Struct. Biol. (2000) 10:401-404. 91. ROGERS DJ, RANDOLPH SE: The global spread of malaria in a future, warmer world. Science (2000) 289:1763-1766. 77. SHUKER SB, HAJDUK PJ, MEADOWS RP, FESIK SW: Discovering high-affinity ligands for proteins: SAR by NMR. Science (1996) 274:1531-1534. 92. REITER P: Malaria and global warming in perspective? Emerg. Infect. Dis. (2000) 6:438-439. 93. 78. ROSS A, SCHLOTTERBECK G, KLAUS W, SENN H: Automation of NMR measurements and data evaluation for systematically screening interactions of small molecules with target proteins. J. Biomol. NMR (2000) 16:139-146. REITER P: From Shakespeare to Defoe: malaria in England in the Little Ice Age. Emerg. Infect. Dis. (2000) 6:1-11. 94. DYE C, REITER P: Climate change and malaria: temperatures without fevers? Science (2000) 289:1697-1698. 95. SNOW K: Could malaria return to Britain? Biologist (London) (2000) 47:176-180. 96. BECKER A, SCHLICHTING I, KABSCH W, SCHULTZ S, WAGNER AF: Structure of peptide deformylase and identification of the substrate binding site. J. Biol. Chem. (1998) 273:11413-11416. 79. SERERO A, GIGLIONE C, MEINNEL T: Seeking new targets for antiparasitic agents. Trends Parasitol. (2001) 17:7-8. 80. GREEN BG, TONEY JH, KOZARICH JW, GRANT SK: Inhibition of bacterial peptide deformylase by biaryl acid analogs. Arch. Biochem. Biophys. (2000) 375:355-358. 81. JAYASEKERA MM, KENDALL A, SHAMMAS R et al.: Novel nonpeptidic inhibitors of peptide deformylase. Arch. Biochem. Biophys. (2000) 381:313-316. 82. 83. 84. 85. •• 86. 87. BROUGHTON BJ, CHAPLEN P, FREEMAN WA et al.: Studies concerning the antibiotic actinonin. Part VIII. Structure- activity relationships in the actinonin series. J. Chem. Soc. [Perkin 1] (1975) 9:857-860. BEELEY NR: Can peptides be mimicked? Drug Discov. Today (2000) 5:354-363. STEWARD WP, THOMAS AL: Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin. Investig. Drugs (2000) 9:2913-2922. CLEMENTS JM, BECKETT RP., BROWN A. et al.: Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 2001 45:563-570. First report of a orally bioavailable anti-PDF drug with potent antibacterial effect. CHEN D et al.: In vivo evaluation of VRC3375, a potent peptide deformylase inhibitor, Abstract No. 2175. Interscience Conference on Antimicrobial Agents and Chemotherapy - 40th Meeting (Part VII) Toronto, Canada, 17-20 September 2000, [Meeting News] Investigational Drugs daily highlights, 27th September 2000. (2000). MACPHERSON LJ, BAYBURT EK, CAPPARELLI MP et al.: Discovery of CGS 27023A, a non-peptidic, potent and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. (1997) 40:2525-2532. Websites 101. Http://www.ncbi.nlm.nih.gov/BLAST/ The Blast server at NCBI; link to PSI BLAST 102. Http://megasun.bch.umontreal.ca/ogmp/projects/ot her/mtcomp.html List of all published complete organelle sequences 103. Http://www.cbs.dtu.dk/services/TargetP/ TargetP 104. Http://www.expasy.ch/swissmod/ Swiss-Model 105. Http://www.ebi.ac.uk/blast2/parasites.html Parasite BLAST at EMBL 106. Http://www.sanger.ac.uk/DataSearch/ BLAST at Sanger centre 107. Http://www.tigr.org/tdb/parasites/ TIGR Parasites Database 108. Http://plasmodiumdb.cis.upenn.edu/ Plasmodium unified database 109. Http://www.dbbm.fiocruz.br/parasite-genome/paraT able.html Link to parasite genome databases and genome research resources 110. Http://caroll.vjf.inserm.fr/trans/DEF.html Compilation of peptide deformylases sequences and alignments. 88. WINSTANLEY PA: Chemotherapy for falciparum malaria: the armoury, the problems and the prospects. Parasitol. Today (2000) 16:146-153. 111. Http://martin.parasitology.mcgill.ca/jimspage/BIOP AGE/CONT.HTM Parasites dictionary 89. DOVE A: New economic analysis draws big money to malaria. Nature Med. (2000) 6:612. 112. Http://www.nature.com/nm/special_focus/malaria/ Special focus of Nature Medicine on malaria © Ashley Publications Ltd. All rights reserved. Emerging Therapeutic Targets (2001) 5(1) Giglione & Meinnel 57 113. Http://www.malaria.org/ Malaria foundation international Carmela Giglione & Thierry Meinnel† Institut des Sciences Végétales, UPR2355, Centre National de la Recherche Scientifique, Bâtiment 23, 1 avenue de la Terrasse, F-91198 Gif-sur-Yvette cedex, France. Tel.: 33+1 69 82 36 12; Fax: 33+1 69 82 36 07; E-mail: [email protected] © Ashley Publications Ltd. All rights reserved. Emerging Therapeutic Targets (2001) 5(1)